Anaplastic lymphoma kinase (ALK) was involved in the development of various cancer
types. Although several ALK inhibitors have been advanced to clinical trials, the emergence …

Recently, proteolysis targeting chimera (PROTAC) technology is highlighted in drug
discovery area as a new therapeutic approach. PROTAC as a heterobifunctional molecule is …

A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and
synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two …

Anaplastic lymphoma kinase (ALK) activation has been associated with many types of
human cancer. Significant efforts have been devoted to the development of ALK inhibitors to …

Fusion proteins of the anaplastic lymphoma kinase (ALK) are promising therapeutic targets
for cancer and other human diseases, especially for non-small cell lung cancer (NSCLC) …

Abstract EML4-ALK and NPM-ALK fusion proteins possess constitutively activated ALK
(anaplastic lymphoma kinase) activity, which in turn leads to the development of non-small …

Combination of different molecular target inhibitors is an available method to improve the
therapeutic effect on tumors. Herein, to achieve both tumor cell targeting and ALK …

As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase
(ALK) has been validated to play important roles in various cancers, especially anaplastic …

We present the development of the first small molecule degraders that can induce anaplastic
lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC) …

In anaplastic large‐cell lymphomas, chromosomal translocations involving the kinase
domain of anaplastic lymphoma kinase (ALK), generally fused to the 5'part of the …